Biogen to acquire RayThera for up to $1bn

Biogen is to acquire RayThera, a biotechnology company specialising in small-molecule therapies for immunology, for up to $1bn. The proposed acquisition will add anti-inflammatory candidates to Biogen, including RayThera’s lead asset. Biogen will assume responsibility for development, manufacturing, and global commercialisation of the assets. Credit: Melnikov Dmitriy / Shutterstock.com. Biogen has entered a definitive agreement to acquire RayThera, a biotechnology company specialising in small-molecule therapies for immunology, for up to $1bn. The deal value comprises an upfront payment and further payments tied to the achievement of future clinical and regulatory milestones. Immuno-oncology (IO) Thematic Intelligence Go deeper with GlobalData…

Source: Pharmaceutical Technology